Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma

Combined inhibition of BRAF and MEK1/2 (CIBM) improves therapeutic efficacy of BRAF-mutant melanoma. However, drug resistance to CIBM is inevitable and the drug resistance mechanisms still remain to be elucidated. Here, we show that BMK1 pathway contributes to the drug resistance to CIBM. Considerin...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Chengli, Wang, Lina, Xu, Qiang, Wang, Kai, Xie, Dan, Yu, Zhe, Jiang, Kui, Liao, Lujian, Yates, John R., Lee, Jiing-Dwan, Yang, Qingkai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384194/
https://www.ncbi.nlm.nih.gov/pubmed/28387310
http://dx.doi.org/10.1038/srep46244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384194/
https://www.ncbi.nlm.nih.gov/pubmed/28387310
http://dx.doi.org/10.1038/srep46244

Ejemplares similares